Skip to content
DataLookout
Menu

SAA MSCNCT07903649

A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Combined With Standard Immunosuppressants in the Treatment of Children With Severe Aplastic Anemia

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Complete response rate (CR) at 6 months of administration
Timeframe: From the start of treatment to the cessation of treatment for 6 months

Secondary (1)

Partial hematological response rate (PR) and total hematological response rate (OR) at 6 months of administration

Arms and interventions

Group AExperimental

Standard immunosuppressive (ATG/ALG)therapy for acquired severe aplastic anemia in children

Group BExperimental

Umbilical cord mesenchymal stem cells combined with standard immunosuppressants (UC-MSC+ATG/ALG) for the treatment of severe acquired aplastic anemia in children anemia

Other: Umbilical Cord Mesenchymal Stem Cells with ATG/ALG

Drugs: ATG/ALG

Sites

1 site in 1 country

  • State key laboratory of experimental hematology,National clinical Research center for blood diseasesTianjin, Tianjin Municipality, China